concentration (before and after treatment) were assayed with routine methods. DAS 28 was calculated with commonly used formula; glomerular filtration rate (GFR) was estimated by the Cockroft-Gault (CG) formula. The characteristics of the patients (ESR, CRP, DAS 28, serum creatinine level and GFR) before and after the infusion of infliximab are shown in Table 1 . The results were expressed as mean ± standard deviation (SD). Differences were tested for significance using the Student's t-test or the Wilcoxon test where appropriate. Correlations were assessed using Spearman's rank correlation.
The results are shown in Table 1 . After one dose of infliximab, there was a significant increase in mean cystatin C level. Creatinine level and GFR did not change significantly. There was a significant decrease in the disease activity (ESR, CRP, DAS 28). There was no statistical correlation between the evaluated parameters.
In the currently published literature, the opinions on influence of inflammatory state on serum cystatin level are controversial. Karstila et al. [4] did not find any influence of inflammatory parameters (CRP, ESR) on cystatin C levels. Knight et al. [1] shown that higher serum CRP levels are associated with higher serum cystatin C levels.
In contrast, Bokarewa et al. [5] proved that in patients with RA, there is relationship between serum cystatin C level and serum amyloid A level (SAA), an acute phase reactant. Cystatin C is thought to bind SAA and therefore its serum level might be decreased in patients with active RA.
Probably the increase in serum cystatin C level in patients with RA after one dose of infliximab in this study is caused by the decrease in serum SAA, as a result of decrease in the inflammatory process [5] and is not dependent on the renal function. However, there was no statistically significant correlation between serum cystatin C level and the acute phase reactants. Further investigations are required before firm conclusions can be drawn regarding the influence of infliximab on serum cystatin C level.
